Ankündigung • Jan 27
DexTech Medical Ab's Myeloma Study, Completes At the End of February 2026, Concludes with Continued Strong Results DexTech Medical AB (publ) announced that the study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of OsteoDex (ODX) are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Udevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Adult myeloma patients with progressive treatment-resistant disease, who have previously received 1-5 prior lines of therapy, are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. The last patient in dose group 2 (6mg/kg) was finished in week 50 (7 doses) and has had his last visit. The patient then continued to have stable disease. All patients in dose group 3 (9mg/kg) have achieved stable disease and will be completed by the end of February. No significant ODX related side effects have been noted. Patients with stable disease after completion of ODX treatment are followed until new progress to map how long the disease-inhibiting effect persists. Data obtained so far show that the disease-inhibiting effects in some cases persists for months and at most up to six months without initiation of other cancer treatment. The results show that all patients responded positively to the ODX treatment, with a transition from progressive disease to stable disease. Ankündigung • Dec 05
DexTech Medical's Myeloma Study (ODX-MM-001), Dose Group 2 and Dose Group 3 DexTech Medical AB (publ) announced that the study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Udevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Adult myeloma patients with progressive, treatment-resistant, disease, who have previously received 1-5 prior lines of treatment are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. The last patient in dose group 2 (6mg/kg) is expected to be finished at week 50 (7 doses). After 6 doses, the patient has still maintained their achieved stable disease, i.e. the progression verified prior to the start of treatment has stopped. The other 3 patients in dose group 2 have, after completion of ODX treatment and the disease was stable, now returned to their progressive disease. The first patient in dose group 3 (9mg/kg) has received 3 doses to date. Here, too, the progressive disease has turned into a stable one. A further 2 patients in dose group 3 have only recently started their ODX treatment. This means that so far, 9/9 (100%) of patients have responded positively to ODX treatment (transition from progressive disease to stable disease). The patients are followed as planned after completion of ODX treatment; this is to map when the disease progresses again. The disease-inhibiting effect persists in some cases even after postponed ODX treatment, at most up to six months. Ankündigung • Oct 17
DexTech Medical's Myeloma Study, Dose Group 2, DMC Gives OK for Dose Group 3 DexTech Medical AB (publ) announced that the study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Udevalla Hospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Adult myeloma patients with progressive treatment-resistant disease, who have previously received 1-5 prior lines of therapy, are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. Dose group 2 (6mg/kg) has been fully recruited. Two patients in dose group 2 have progressive disease after completion of treatment. The other 2 patients will finish the treatment in early December. The DMC (Independent Data Monitoring Committee) approves the continuation to dose group 3. No ODX related serious side effects have been noted. A new patient for dose group 3 has been screened. Follow-up of all patients who have achieved stable disease is done to determine how long the disease-slowing effect persists after the ODX treatment has been discontinued, i.e., until new progress. Ankündigung • Aug 21
DexTech Medical AB Announces Study of ODX Treatment for Adult Myeloma Patients with Progressive Treatment-Resistant Disease DexTech Medical AB announced that the study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of ODX are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University hospital Huddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla Hospital". Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Adult myeloma patients with progressive treatment-resistant disease, who have previously received 1-5 prior lines of therapy, are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response. Dose group 2 (6mg/kg) is expected to be fully recruited in August/September. Two patients in dose group 2 have progressive disease after completion of treatment. This means that so far, 67% of patients have responded positively to ODX treatment (transition from progressive disease to stable disease). No significant, ODX-related, side effects have been noted. Follow-up of all patients who have achieved stable disease is done to determine how long the disease-inhibiting effect persists after the ODX treatment has been discontinued. Follow-up of patients from dose group 1 shows that the disease-inhibiting impact continued, even after discontinuation of ODX. At most, the disease-inhibiting effects lasted just over six months without the initiation of other cancer treatment. A meeting of the DMC (the independent data monitoring committee) is expected to be held in September to approve the continuation to dose group 3. Ankündigung • May 21
Dextech Medical's Patent Application Regarding Gmp Manufacturing of Osteodex is approved OsteoDex is DexTech's lead candidate for the treatment of castration-resistant prostate cancer and has completed clinical phase 2. In October 2023, the Company filed a patent application with the EPO (European patent office, application No. 23203437.1). The application concerned GMP (Good Manufacturing Practice) manufacturing of OsteoDex. The application has now been approved, and a patent has been granted. The patent is of great importance for the continued clinical development of OsteoDex and future market exclusivity. The patent is valid until 2045 and is very positive for the Company's partnership/out-licensing talks. New Risk • May 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue is less than US$1m (kr4.2m revenue, or US$438k). Minor Risk Market cap is less than US$100m (kr110.9m market cap, or US$11.4m). Reported Earnings • May 02
Third quarter 2025 earnings released: kr0.067 loss per share (vs kr0.077 loss in 3Q 2024) Third quarter 2025 results: kr0.067 loss per share (improved from kr0.077 loss in 3Q 2024). Revenue: kr515.0k (down 59% from 3Q 2024). Net loss: kr1.24m (loss narrowed 12% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Ankündigung • Apr 23
DexTech Medical AB's Myeloma Study, Strong Follow-Up Results DexTech Medical AB announced that the study is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. The treatment boasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed treatment-resistant disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with a secondary objective to determine indications of treatment response. The follow-up shows interesting results. At the first follow-up after completion of treatment, all patients in dose group 1, (four patients, 3mg/kg) have stable disease. The patients have then been followed, without other cancer treatment, until new progression of the disease (according to the amendment). Time to progress was 89 days, 59 days, 188 days and 39 days. None of the patients had any significant side effects from the ODX treatment. The results indicate that ODX is effective against multiple myeloma and that the slowing effect remains over time without other treatment. Reported Earnings • Feb 28
Second quarter 2025 earnings released: kr0.052 loss per share (vs kr0.058 loss in 2Q 2024) Second quarter 2025 results: kr0.052 loss per share (improved from kr0.058 loss in 2Q 2024). Revenue: kr1.53m (up 75% from 2Q 2024). Net loss: kr961.0k (loss narrowed 11% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 25
First quarter 2025 earnings released: kr0.062 loss per share (vs kr0.05 loss in 1Q 2024) First quarter 2025 results: kr0.062 loss per share (further deteriorated from kr0.05 loss in 1Q 2024). Revenue: kr585.0k (down 65% from 1Q 2024). Net loss: kr1.14m (loss widened 24% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Ankündigung • Sep 25
Dextech Medical AB to Report Q1, 2025 Results on Oct 24, 2024 Dextech Medical AB announced that they will report Q1, 2025 results on Oct 24, 2024 Ankündigung • Aug 13
Dextech Medical AB Announces Continued Positive Results from Myeloma Study Dextech Medical AB announced continued positive results from myeloma study. The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. The first dose group (3mg/kg) is now ready, and the DMC (Data Monitoring Committee) has approved the start of dose group 2 (6mg/kg). DMC assesses all analysis results to decide on the next higher dose. No side effects related to OsteoDex have been noted. All patients show a decrease in skeletal biomarkers. Three out of four patients have stable disease after completion of treatment (stable = no progression of the disease). Patients with stable disease will be followed up until new progress according to the approved amendment, which provides information on how long the treatment effect lasts. The study includes up to a maximum of 20 patients and is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. More hospitals may be involved later. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr. Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (progressive) treatment-resistant disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with a secondary objective to determine treatment response. The study is expected to be completed in Q2, 2025. Reported Earnings • Apr 28
Third quarter 2024 earnings released: kr0.077 loss per share (vs kr0.079 loss in 3Q 2023) Third quarter 2024 results: kr0.077 loss per share (improved from kr0.079 loss in 3Q 2023). Revenue: kr1.26m (down 59% from 3Q 2023). Net loss: kr1.42m (loss narrowed 3.2% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Ankündigung • Apr 16
DexTech Medical Announces New Positive Results from the Myeloma Study DexTech Medical AB announced new positive results from the myeloma study. The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). progressive disease means that the disease progresses and does not respond to existing treatment. A patient who has shown a sharp reduction in skeletal biomarkers and who has now completed his treatment is found to have stable disease with continued low values of markers that reflect skeletal activity. Stable disease means that the disease does not develop/progress, which is very positive. The company now intends to follow patients with stable disease for up to 2 years after completion of OsteoDex treatment. A so-called amendment has been submitted to the relevant authorities. The follow-up provides the Company with valuable information about how long OsteoDex's effect lasts. The study covers a total of max. 20 patients and is being conducted at Karolinska University Hospital Huddinge and Uddevalla Hospital. More hospitals may be involved at a later date. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr. Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (progressive) refractory disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with the secondary objective to determine treatment response. The recruitment of patients is relatively slow (competing studies, inclusion requirements), which means that the conclusion of the study is postponed somewhat to second quarter, 2025. This means that study costs are also postponed, which means that the Company is financed throughout 2025. New Risk • Apr 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr107.2m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (kr7.3m revenue, or US$676k). Market cap is less than US$10m (kr107.2m market cap, or US$9.99m). Reported Earnings • Feb 16
Second quarter 2024 earnings released: kr0.058 loss per share (vs kr0.065 loss in 2Q 2023) Second quarter 2024 results: kr0.058 loss per share (improved from kr0.065 loss in 2Q 2023). Revenue: kr879.0k (down 71% from 2Q 2023). Net loss: kr1.08m (loss narrowed 9.9% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. New Risk • Jan 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Revenue is less than US$1m (kr9.4m revenue, or US$898k). Minor Risk Market cap is less than US$100m (kr133.1m market cap, or US$12.7m). Ankündigung • Jan 24
Dextech Medical AB Announces Positive Results from the Myeloma Study DexTech Medical AB announced positive results from the myeloma study. The first test results from patient 1 have been received and show a very strong effect on the marker of osteoDex. The baseline value for CTX decreases by about 80% after 3 doses of OsteoDex. The other values are fairly constant (cf. baseline). Osteoclasts break down bone (resorb) and CTX reflects osteoDex activity that is elevated in multiple myeloma. The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. The study includes a total of 20 patients and will initially be conducted at three hospitals in Sweden: Karolinska University Hospital Huddinge, Uddevalla Hospital and Sodersjukhuset in Stockholm. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dratarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (pro progressive) refractory disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with the secondary objective to determine treatment response. The study is expected to be completed in fourth quarter, 2024. Ankündigung • Dec 13
DexTech Medical Informs About the Myeloma Study, the First Patient Is Treated DexTech Medical AB announced that the Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. The study includes a total of 20 patients and will initially be conducted at three hospitals in Sweden: Karolinska University Hospital Huddinge, Uddevalla Hospital and Sodersjukhuset in Stockholm. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dratarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University HospitalHuddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (pro progressive) refractory disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with the secondary objective to determine treatment response. Biochemical markers are continuously analyzed, and the first assay results are expected in first quarter-24. The study is expected to be completed in fourth quarter, 2024. The work to seek partnerships regarding continued clinical development of OsteoDex - mCRPC towards phase 3 - is ongoing. The Company's synthesis patent application, filed with the European Patent Office (EPO.org) in October -23, is of great importance for the Company's opportunities for partnership as well as positive results from the Company's MM study. The conditions for the patent application to be granted are good, resulting in market exclusivity until 2044. Without consulting the results from the MM study, Osteodex's positive effect on bone-degrading bone cells and the absence of serious side effects are well documented and will probably be confirmed in the MM study as well. Reported Earnings • Oct 29
First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.044 loss in 1Q 2023) First quarter 2024 results: kr0.05 loss per share (further deteriorated from kr0.044 loss in 1Q 2023). Revenue: kr1.65m (up 75% from 1Q 2023). Net loss: kr917.0k (loss widened 13% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. Ankündigung • Sep 29
Dextech Medical AB, Annual General Meeting, Oct 31, 2023 Dextech Medical AB, Annual General Meeting, Oct 31, 2023, at 10:00 Central European Standard Time. Location: IVA's conference centre, Kungl Royal Swedish Academy of Engineering Sciences, Grev Turegatan 16, Stockholm Stockholm Sweden Agenda: To consider resolution on adoption of the profit and loss account and balance sheet; to consider resolution on the appropriation of the company's profit or loss in accordance with the adopted balance sheet; and to consider other items. Reported Earnings • Aug 31
Full year 2023 earnings released: kr0.25 loss per share (vs kr0.31 loss in FY 2022) Full year 2023 results: kr0.25 loss per share (improved from kr0.31 loss in FY 2022). Revenue: kr8.71m (up 180% from FY 2022). Net loss: kr4.59m (loss narrowed 13% from FY 2022). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings. New Risk • Aug 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (kr9.9m revenue, or US$918k). Market cap is less than US$10m (kr77.6m market cap, or US$7.17m). Minor Risk Share price has been volatile over the past 3 months (9.0% average weekly change). Reported Earnings • Apr 29
Third quarter 2023 earnings released: kr0.079 loss per share (vs kr0.061 loss in 3Q 2022) Third quarter 2023 results: kr0.079 loss per share (further deteriorated from kr0.061 loss in 3Q 2022). Revenue: kr3.08m (up kr2.93m from 3Q 2022). Net loss: kr1.46m (loss widened 29% from 3Q 2022). Reported Earnings • Feb 17
Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.076 loss in 2Q 2022) Second quarter 2023 results: kr0.065 loss per share. Revenue: kr3.03m (up kr3.00m from 2Q 2022). Net loss: kr1.20m (loss widened 5.5% from 2Q 2022). Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Chairman of the Board Andreas Segerros was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 02
First quarter 2023 earnings released: kr0.044 loss per share (vs kr0.063 loss in 1Q 2022) First quarter 2023 results: kr0.044 loss per share (improved from kr0.063 loss in 1Q 2022). Revenue: kr943.0k (up kr900.0k from 1Q 2022). Net loss: kr815.0k (loss narrowed 14% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Ankündigung • Sep 28
Dextech Medical AB Announces Upcoming Multiple Myeloma Study Dextech Medical AB announced the upcoming multiple myeloma study. The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the Medical Products Agency on August 10, 2022. The study will include 20 patients and be conducted at 4-5 hospitals in Sweden and other Nordic countries. Studyn is expected to start in First Quarter 2023 and be completed during fourth quarter, 2024. Principal investigator (PI) is Dr. Katarina Uttervall, MD, PhD, Division of Hematology/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. The study duration for each individual patient is 14 weeks, from screening to follow-up visits. Each patient will receive OsteoDex every two weeks, a maximum of 7 doses. Adult MM patients with recurrent/treatment-resistant disease, who received 1-3 previous lines of therapy, will be included. The primary objective is to confirm safety and tolerability. The secondary objective is to determine treatmentresponse, change in the level of disease-related biomarkers, and documentation of quality of life (QoL scores). Reported Earnings • Sep 02
Full year 2022 earnings released: kr0.31 loss per share (vs kr0.41 loss in FY 2021) Full year 2022 results: kr0.31 loss per share (up from kr0.41 loss in FY 2021). Revenue: kr3.12m (up 391% from FY 2021). Net loss: kr5.27m (loss narrowed 13% from FY 2021). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Ankündigung • Aug 11
Dextech Medical AB Announces Application Approval for Myeloma Study from Medical Products Agency Dextech Medical AB announced the application for a phase1 study regarding OsteoDex's effect on patients with multiple myeloma that was submitted to the Medical Products Agency on June 23, 2022 has been approved and granted permission August 10, 2022. The study will include 20 patients and be conducted at 5 hospital centers in Sweden and Norway. The start of the study is expected to be third quarter of 2022 and first quarter of 2023 and is expected to be completed third quarter of 2024. Ankündigung • May 12
Dextech Medical AB Appoints Andreas Segerros as A New Ordinary Board Member Dextech Medical AB at its EGM held on May 11, 2022 decided to elect Andreas Segerros as a new ordinary board member. At the subsequent statutory board meeting, Andreas Segerros was elected new chairman of the board. Reported Earnings • May 01
Third quarter 2022 earnings released: kr0.061 loss per share (vs kr0.10 loss in 3Q 2021) Third quarter 2022 results: kr0.061 loss per share (up from kr0.10 loss in 3Q 2021). Net loss: kr1.14m (loss narrowed 24% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Hakan Astrom was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Feb 19
DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex DexTech Medical will soon advance into the clinical phase in multiple myeloma with the main candidate OsteoDex, which has shown promising phase II clinical results in metastatic castration-resistant prostate cancer. Reported Earnings • Feb 16
Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations Second quarter 2022 results: kr0.076 loss per share (up from kr0.10 loss in 2Q 2021). Net loss: kr1.14m (loss narrowed 27% from 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 03
Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: kr635.0k (up 6.5% from FY 2020). Net loss: kr6.08m (loss narrowed 21% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 01
Full year 2021 earnings released: kr0.41 loss per share (vs kr0.52 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: kr635.0k (up 6.5% from FY 2020). Net loss: kr6.08m (loss narrowed 21% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Ankündigung • Aug 25
DexTech Medical AB Plans New Clinical Study on Multiple Myeloma DexTech announces that OsteoDex´ (ODX) pre-clinical results regarding the effect on multiple myeloma (MM) are so convincing that the company now plans a clinical "proof of concept study" (short study with a limited number of patients). MM is a form of blood cancer starting in plasma cells in the bone marrow and, similar to skeletal metastases in prostate cancer (CRPC), causes breakdown of bone. MM is an incurable cancer for which a number of different drugs are used to slow down the disease. Patients eventually become resistant to existing drugs, that often have severe side effects. ODX's unique mechanism of action, together with very mild side effects, makes the drug a strong candidate for treatment of MM as well. The company believes that, given MM's market size and ODX's clear potential for the disease, it is of the higher priority to obtain supplementary clinical data. Ankündigung • May 12
DexTech Medical AB Confirms Very Positive Results from Myeloma Studies Dextech Medical AB announced positive results from initial in vitro studies regarding OsteoDex (ODX) effect on multiple myeloma (MM). MM is a form of blood cancer that develops in the bone marrow and at the same time causes the skeleton to break down. The disease is not curable, but a number of different treatments are used to slow down the process. Common to the treatments is that these often give severe side effects. ODX mechanism of action, i.e., Inhibition of bone-degrading bone cells (osteoclasts) and tumor cell toxicity, together with very mild side effects, appear to be ideal properties for the treatment of MM. The positive results have now been confirmed in extended in vitro studies and show a strong tumor cell inhibitory effect of ODX, up to 10 times stronger effect compared to CRPC cells. Reported Earnings • Apr 25
Third quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 3Q 2020) Third quarter 2021 results: Net loss: kr1.50m (loss narrowed 20% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 12% per year. Is New 90 Day High Low • Feb 15
New 90-day high: kr59.40 The company is up 16% from its price of kr51.20 on 17 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. Reported Earnings • Feb 03
Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.13 loss in 2Q 2020) Second quarter 2021 results: Net loss: kr1.55m (loss narrowed 19% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Feb 02
DexTech Medical AB Receives Positive Results Regarding Multiple Myeloma DexTech Medical AB can announce that the company is expanding its preclinical program to also include research into the effect of OsteoDex on multiple myeloma, (MM), in vitro, cell cultures. MM is a malignant tumor disease of the bone marrow, which causes the skeleton to break down. MM is an incurable disease where a number of different treatments are used to slow down the process. The treatments often have severe side effects. The company sees OsteoDex as very promising for the treatment of MM based on its mechanism of action and mild side effects. In summary, a potent treatment effect is seen, even at low concentrations of OsteoDex. Effect at low concentration is an important result in vitro testing and indicates possible effect in vivo (in living organism). The observed cell killing effect is superior to the compared substance, Melphalan, which is a standard drug in the treatment of MM. Is New 90 Day High Low • Jan 18
New 90-day low: kr45.20 The company is down 13% from its price of kr51.80 on 20 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Reported Earnings • Oct 23
First quarter earnings released Over the last 12 months the company has reported total losses of kr7.25m, with losses narrowing by 14% from the prior year.